Addex initiates second Phase IIb GERD trial
Study ADX10059-204 is a double-blind, placebo-controlled, multi-center European Phase IIb trial in about 90 gastroesophageal reflux disease (GERD) patients known to respond well to proton pump inhibitors (PPI).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.